Korea s antitrust regulator said Thursday it has decided to slap combined fines of 40.7 billion won ($32.2 million) on 32 pharmaceutical companies involved in collusive practices in the government s procurement bids.
Dongwon Industries, the holding firm of Dongwon Group, signed a memorandum of understanding with Boryung Partners recently to acquire a controlling stake in Boryung Biopharma, which is estimated to be worth 500 billion won ($384 million). Once the acquisition deal is finished, Dongwon Group will be able to enter the biopharmaceutical industry for the first time in its 54-year history.
A large number of consortiums of pharmaceutical-bio companies and research institutes to develop mRNA (messenger ribonucleic acid) vaccines are rapidly being es